CD4 <sup>+</sup> tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts-Reference-Cited by-同舟云学术

CD4 ⁺ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts

Published:2024-08-27 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Jiménez-Reinoso Anaïs¹²³^ORCID,Molero-Abraham Magdalena⁴⁵^ORCID,Cirauqui Cristina⁵^ORCID,Blanco Belén¹²³^ORCID,Garrido-Martin Eva M.⁵⁶^ORCID,Nehme-Álvarez Daniel¹²^ORCID,Domínguez-Alonso Carmen¹²³^ORCID,Ramírez-Fernández Ángel¹²³^ORCID,Díez-Alonso Laura¹²³^ORCID,Nuñez-Buiza Ángel⁵^ORCID,González-Murillo África⁷⁸⁹^ORCID,Tobes Raquel¹⁰^ORCID,Pareja Eduardo¹⁰^ORCID,Ramírez-Orellana Manuel⁷⁸⁹^ORCID,Rodriguez-Peralto José Luis⁶¹¹¹²¹³^ORCID,Ferrer Irene⁵⁶^ORCID,Zugazagoitia Jon⁴⁵⁶¹⁴^ORCID,Paz-Ares Luis⁵⁶¹⁴¹⁵^ORCID,Álvarez-Vallina Luis¹²³^ORCID

Affiliation:

1. Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain

2. Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain

3. H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

4. Tumor Microenvironment and Immunotherapy Research Group, Madrid, Spain

5. H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Sanitaria 12 de Octubre (imas12), CNIO, Madrid, Spain

6. Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain

7. Advanced Therapies Unit, Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

8. Fundación de Investigación Biomédica, Hospital Infantil Universitario Niño Jesús, Madrid, Spain

9. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain

10. Alamo blanco Research Association, Granada, Spain

11. Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain

12. Department of Pathology, Complutense University, Madrid, Spain

13. Cutaneous Oncology Group, Madrid, Spain

14. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain

15. Department of Medicine, Complutense University, Madrid, Spain

Funder

Spanish Ministry of Science and Innovation

Instituto de Salud Carlos III

Comunidad de Madrid

Fundación CRIS contra el Cáncer

Asociación Española contra el Cáncer

Fundación ‘‘La Caixa’’

Fundación de Investigación Biomédica 12 de Octubre Programa Investiga

ISCIII

European Comission (TOPMESO Transcan), and the Fundación CRIS contra el Cáncer

AECC

predoctoral fellowship

Rio Hortega fellowship

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2392897

Reference48 articles.

1. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

2. Tumor-Infiltrating Lymphocyte Therapy and Neoantigens

3. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

4. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

5. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study